The two products are polyp detection software EndoScreener and a histopathology software product, according to a March 22 news release.
EndoScreener received FDA approval in November 2021, and the histopathological product is in the presubmission stage.
In four randomized controlled trials, EndoScreener increased detected adenoma by 32.2 percent and reduced adenoma miss rate by 35.6 percent, the news release said.
The histopathological product will be used to help with localizing high-grade dysplasia in whole-slide imaging.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
